Summary
Eli Lilly and Company (LLY) filed an 8-K on April 30, 2019, to report its financial results for the first quarter and three-month period ended March 31, 2019. The filing primarily incorporates by reference a press release (Exhibit 99.1) which details the company's operational and financial performance. Investors should consult this press release for specific financial figures, revenue drivers, and any forward-looking statements or guidance provided by the company. While the 8-K itself is brief, it serves as the official notification for the release of crucial quarterly financial information. The attached press release is the key document for understanding Lilly's performance in Q1 2019, including key metrics such as revenue, earnings, and potentially updates on its product pipeline and strategic initiatives.
Key Highlights
- 18-K filed on April 30, 2019, reporting Q1 2019 results.
- 2Key financial and operational data for the quarter ended March 31, 2019, are provided in Exhibit 99.1.
- 3Exhibit 99.1 is a press release announcing the Q1 2019 results.
- 4Information is furnished and not deemed 'filed' for Section 18 of the Exchange Act.
- 5The filing incorporates the press release by reference into Item 2.02 and Item 9.01.
- 6Investors should refer to the attached press release for detailed financial performance and updates.